- Home
- ATHA vs CARM Comparison
ATHA vs CARM Comparison
Compare ATHA & CARM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- CARM
- Stock Information
- Founded
- ATHA 2011
- CARM 2016
- Country
- ATHA United States
- CARM United States
- Employees
- ATHA N/A
- CARM N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- CARM Biotechnology: Pharmaceutical Preparations
- Sector
- ATHA Health Care
- CARM Health Care
- Exchange
- ATHA Nasdaq
- CARM Nasdaq
- Market Cap
- ATHA 14.8M
- CARM 12.1M
- IPO Year
- ATHA 2020
- CARM N/A
- Fundamental
- Price
- ATHA $3.82
- CARM $0.16
- Analyst Decision
- ATHA
- CARM Hold
- Analyst Count
- ATHA 0
- CARM 5
- Target Price
- ATHA N/A
- CARM $0.90
- AVG Volume (30 Days)
- ATHA 48.3K
- CARM 2.1M
- Earning Date
- ATHA 11-06-2025
- CARM 11-06-2025
- Dividend Yield
- ATHA N/A
- CARM N/A
- EPS Growth
- ATHA N/A
- CARM N/A
- EPS
- ATHA N/A
- CARM N/A
- Revenue
- ATHA N/A
- CARM $10,767,000.00
- Revenue This Year
- ATHA N/A
- CARM N/A
- Revenue Next Year
- ATHA N/A
- CARM N/A
- P/E Ratio
- ATHA N/A
- CARM N/A
- Revenue Growth
- ATHA N/A
- CARM N/A
- 52 Week Low
- ATHA $2.20
- CARM $0.14
- 52 Week High
- ATHA $8.26
- CARM $1.27
- Technical
- Relative Strength Index (RSI)
- ATHA 62.48
- CARM 29.49
- Support Level
- ATHA $3.61
- CARM $0.24
- Resistance Level
- ATHA $4.04
- CARM $0.29
- Average True Range (ATR)
- ATHA 0.25
- CARM 0.03
- MACD
- ATHA -0.17
- CARM -0.01
- Stochastic Oscillator
- ATHA 14.29
- CARM 5.24
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About CARM Carisma Therapeutics Inc.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.